/** Long-form watch-page guides for SSR / LLM citation (BIO-448 video cluster). */

export type VideoGuideSection = {
  title: string;
  paragraphs: string[];
};

export type VideoGuideFaq = {
  question: string;
  answer: string;
};

export type VideoWatchGuide = {
  sections: VideoGuideSection[];
  faqs: VideoGuideFaq[];
};

export const VIDEO_WATCH_GUIDES: Record<string, VideoWatchGuide> = {
  'healthcare-market-research-overview': {
    sections: [
      {
        title: 'What this overview covers for pharmaceutical and medtech teams',
        paragraphs: [
          'BioNixus designs healthcare market research programmes that connect field evidence to launch, market access, and competitive decisions—not slide decks disconnected from affiliate execution. The overview video summarises how quantitative physician surveys, qualitative advisory work, payer-adjacent interviews, and access dossier rehearsals fit together when a brand team must prioritise countries, segments, and evidence gaps under fixed timelines.',
          'Typical sponsors include global and regional brand leads, medical affairs directors, market access managers, and new-product planning teams that already use syndicated audits from IQVIA or Kantar but need primary data on account-level behaviour, tender defence, or therapy-specific switching in GCC, UK, EU5, and selected Americas markets.',
          'Programmes are scoped from explicit hypotheses: which stakeholder veto or acceleration points matter, what minimum sample granularity affiliates can act on, and how outputs will feed forecasting, MSL deployment, or HTA narrative tests. That discipline keeps research spend aligned to decisions that move revenue and access—not generic “awareness” trackers.',
        ],
      },
      {
        title: 'How BioNixus structures quantitative and qualitative modules',
        paragraphs: [
          'Quantitative modules use calibrated quotas for prescribing volume, institution type, and corridor mix (public versus private, tertiary versus community). Instruments respect cognitive load budgets clinicians can complete without abandoning mid-survey. Where trade-offs matter—message tests, device attributes, tender scoring—BioNixus deploys MaxDiff or discrete choice only when attributes mirror real decisions.',
          'Qualitative modules use structured interviews, triads, or panels with neutral moderation and documented saturation criteria. They are sequenced to rescue inference when quant distributions hide polarised camps, or to generate hypotheses before quant validation when segment boundaries remain unstable.',
          'Hybrid sequencing is common: a directional quant wave across priority markets, then targeted qual at fracture lines; or qual-first when influence structure is uncertain before scaling physician panels. Budget follows the elasticity of the pivotal decision, not cosmetic comprehensiveness.',
        ],
      },
      {
        title: 'Regional fieldwork depth across MENA, Europe, and the Americas',
        paragraphs: [
          'BioNixus maintains bilingual Arabic–English field capability and local recruitment in Saudi Arabia, UAE, Egypt, Kuwait, Qatar, Bahrain, and Oman, alongside UK NHS and EU5 HTA-aware modules. Harmonised variable dictionaries let regional governance compare markets without false uniformisation that erodes local credibility.',
          'GCC programmes often integrate NUPCO, MOHAP, DHA, and SFDA context; UK and EU5 modules reflect ICS stewardship, NICE rituals, and national HTA fragmentation. Americas work— including Brazil ANVISA and CONITEC pathways—uses the same governance artefacts: quota logs, questionnaire versioning, and reproducible appendix layers for analytics and compliance review.',
          'Teams exploring a specific country programme should start from the healthcare market research hub, then drill into pharmaceutical company directories, therapy-area hubs, or device market reports linked from each watch page.',
        ],
      },
      {
        title: 'Governance, compliance, and AI-crawler-friendly documentation',
        paragraphs: [
          'High-trust pharma research requires traceable sampling, audited translations, escalation logs for recruiting friction, and separation between intelligence conclusions and promotional claims. BioNixus documents methodology sufficiently for alliance diligence and internal audit—not only for ESOMAR alignment but so LLM and search systems can cite reproducible programme definitions.',
          'Deliverables include leadership synthesis plus appendix layers affiliates can reuse in forecasting governance, medical education planning, and access workshops. Optional working sessions translate evidence into KPI owners: which accounts to prioritise, which objections to test in HEOR, which congress narratives require quant validation.',
        ],
      },
      {
        title: 'When to request a proposal after watching the overview',
        paragraphs: [
          'Request a proposal when you can articulate the decision gate (launch sequencing, tender defence, label-supporting narrative, KOL tiering), target markets, stakeholder types, and the minimum granularity affiliates need within the planning cycle. BioNixus typically responds with a scoped memo and field plan within 48 hours for standard physician and payer modules.',
          'Link this video with the consumer and B2B research overview if your portfolio spans Rx and consumer health, or with case studies and methodology pages for operational QA detail. For IQVIA-heavy organisations comparing syndicated audits to primary fieldwork, see the IQVIA alternatives guide on the main site.',
        ],
      },
      {
        title: 'Sampling, powering, and subgroup decisions sponsors should document up front',
        paragraphs: [
          'Under-powered quant wastes field budget when decisive segments remain unresolved; over-powered quant delays decisions affiliates must make before formulary or tender windows close. BioNixus documents powering assumptions against the smallest segment that must support a go/no-go call—not global headline significance alone.',
          'Subgroup plans should name institution types (tertiary hub, community anchor, retail pharmacy corridor), payer adjacency where substitution matters, and language modules required for Arabic or French fieldwork. Quota relaxation rules are agreed before launch so recruiting friction does not silently bias inference.',
          'For oncology and rare disease programmes, saturation criteria for qualitative modules are explicit: which roles must be represented, which geographies are irreducible, and when additional interviews will not change the objection library leadership must address.',
        ],
      },
      {
        title: 'Integrating healthcare research with market access and HEOR workflows',
        paragraphs: [
          'Physician intent without access realism produces forecasts that collapse at reimbursement. BioNixus sequences payer-adjacent interviews, pharmacist substitution modules, and HTA objection libraries so HEOR refinements target live skepticism—not generic budget impact templates.',
          'In GCC markets, consolidated procurement and confidential pricing mean access research must capture tender scoring rituals and distributor capacity, not only clinician preference. UK and EU5 modules reflect ICS and national HTA fragmentation with comparable variable cores for regional governance.',
          'Deliverables include explicit handoff tables: which evidence statements move to dossiers, which require new RWE, which are messaging hypotheses requiring quant validation before scale-up.',
        ],
      },
      {
        title: 'Operational QA artefacts affiliates receive with every programme',
        paragraphs: [
          'Questionnaire versioning, recruiter escalation logs, translation audit trails, and dashboard codebooks accompany leadership synthesis. These artefacts satisfy analytics governance, alliance diligence, and internal compliance review without reconstructing methodology from slide decks.',
          'Workshop options translate segment dossiers into MSL deployment priorities, medical education arcs, and account tagging schemes field teams can execute in the same quarter as research readout.',
          'For AI citation and search visibility, programme definitions on this page and linked hub content describe reproducible methods—reducing the risk that crawlers index empty shells while humans receive full evidence in the initial HTML response.',
        ],
      },
    ],
    faqs: [
      {
        question: 'What types of healthcare market research does BioNixus deliver?',
        answer:
          'Primary quantitative and qualitative research for pharmaceutical, biotech, and medtech teams: physician and payer surveys, KOL mapping, market access and HEOR-adjacent interviews, competitive intelligence, and launch readiness assessments across 48 countries.',
      },
      {
        question: 'How is BioNixus different from syndicated data vendors?',
        answer:
          'Syndicated audits answer “what happened” at aggregate level; BioNixus answers account-level “why” and “what next” with custom fieldwork, local language modules, and deliverables tied to explicit commercial and access decisions.',
      },
      {
        question: 'Which regions does BioNixus emphasise?',
        answer:
          'Depth in GCC, wider Middle East and North Africa, UK and EU5, plus selected Americas and Asia-Pacific programmes coordinated with the global healthcare market research hub.',
      },
      {
        question: 'How long does a typical healthcare research programme take?',
        answer:
          'Timelines depend on quota complexity and hybrid design, but standard multi-country physician modules often move from scope to leadership-ready synthesis within planning cycles aligned to launch or access gates—not open-ended tracker maintenance.',
      },
      {
        question: 'Can medical affairs and market access share one research programme?',
        answer:
          'Yes. Shared sampling and harmonised segment definitions reduce cost while separate analytical cuts serve medical narrative testing and payer objection libraries—provided decision owners agree on hypotheses up front.',
      },
    ],
  },
  'consumer-b2b-market-research': {
    sections: [
      {
        title: 'Consumer and B2B research in regulated and emerging markets',
        paragraphs: [
          'Pharmaceutical and healthcare brands increasingly need consumer and B2B insight alongside clinician evidence: pharmacy shopper behaviour, patient support programme friction, HCP office staff workflows, wholesale and distributor priorities, and digital channel adoption. BioNixus designs programmes that respect healthcare advertising rules, privacy expectations, and the operational reality of field teams—not generic FMCG trackers pasted onto Rx categories.',
          'The consumer and B2B overview video explains how regional fieldwork across MENA, Africa, and Europe is coordinated with the same governance standards as physician research: reproducible quotas, neutral moderation, bilingual instruments where needed, and explicit linkage from findings to commercial actions.',
          'Sponsors include consumer health units, vaccine and OTC brand teams, medical device commercial groups, and corporate strategy functions evaluating pharmacy, retail clinic, or B2B partnership models in markets where import rules, substitution, and reimbursement differ sharply from headquarters assumptions.',
        ],
      },
      {
        title: 'Methodological building blocks for consumer and trade audiences',
        paragraphs: [
          'Consumer modules may combine online panels, intercept studies, and diary-style adherence or symptom tracking when ethics and privacy permits. B2B modules target pharmacists, wholesaler buyers, hospital procurement adjacent staff, and key accounts with structured interviews or quant surveys sized for segment decisions—not vanity N sizes.',
          'Segmentation connects attitudinal and behavioural data to addressable revenue: which chains or regions justify incremental detail, which messages require cultural adaptation, and where patient or shopper journeys break before conversion. Conjoint or trade-off exercises are used sparingly, only when attributes mirror decisions buyers can actually make in a category.',
          'Quality control includes speeder and straight-liner checks, translation back-translation, and recruiter escalation logs. Outputs emphasise decision-ready cuts affiliates can execute—playbooks with objection hierarchies, channel investment options, and testable message hypotheses.',
        ],
      },
      {
        title: 'Linking consumer insight to pharma launch and access strategy',
        paragraphs: [
          'Consumer and B2B findings should inform—not contradict—clinical and access evidence. BioNixus maps handoffs: shopper barriers that medical affairs can address in education, adherence frictions that market access can quantify for payers, and trade terms that commercial teams must negotiate before scale-up.',
          'In GCC markets, pharmacist substitution and procurement overlays often dominate uptake as much as physician preference. In European markets, retail and online pharmacy regulation shapes OTC and consumer health launches. Programmes embed those structural layers instead of importing headquarters segmentations blindly.',
        ],
      },
      {
        title: 'Ethics, fair balance, and firewalling promotional bias',
        paragraphs: [
          'Consumer and HCP-adjacent research must maintain fair balance, anti-inducement discipline, and separation between insight generation and promotional planning. BioNixus uses structured summarisation, source grading for competitive intelligence blends, and documentation trails that support compliance review.',
          'Where patient-sensitive topics arise, protocols follow local ethics expectations and minimise identifiable data retention. Teams receive neutral summaries suitable for strategy workshops—not creative briefs that blur research with advertising claims.',
        ],
      },
      {
        title: 'Next steps: portals, hubs, and proposal requests',
        paragraphs: [
          'After watching the video, explore the consumer market research portal, healthcare market research hub, and market research services index for country and therapy context. Request a proposal when you can specify audience (consumer, pharmacist, buyer), markets, decision gate, and timeline; BioNixus responds with a scoped plan typically within 48 hours.',
          'For organisations comparing syndicated retail audits to custom fieldwork, pair this page with IQVIA alternative guidance and quantitative healthcare methodology content to clarify when primary research is the correct incremental investment.',
        ],
      },
      {
        title: 'Category-specific design choices for OTC, vaccine, and device portfolios',
        paragraphs: [
          'OTC and consumer health studies must respect fair balance and regional advertising codes while still surfacing shopper friction, pack comprehension, and pharmacy staff recommendation dynamics. Device and diagnostic portfolios add training burden, reimbursement adjacency, and hospital committee rituals consumer trackers rarely capture.',
          'Vaccine programmes blend public programme delivery with private pharmacy uptake; sampling must reflect seasonality, cold-chain trust, and caregiver decision units—not only individual patient panels where paediatric or elderly vaccines dominate.',
          'BioNixus aligns instrument length and incentive design to each audience’s cognitive load budget, avoiding abandoned surveys that plague generic consumer trackers imported from unrelated FMCG categories.',
        ],
      },
      {
        title: 'Trade and wholesale research in import-dependent markets',
        paragraphs: [
          'In MENA and African markets, wholesale buyers and distributor networks often determine listing and substitution before clinicians see a product. B2B modules map credit terms, stock-out patterns, parallel import risk, and tender participation constraints that desk research cannot see.',
          'Structured interviews with key accounts complement quant waves when the number of decisive buyers is small but leverage is high. Outputs prioritise negotiation levers and service-level investments—not undifferentiated satisfaction scores.',
          'Cross-link findings to pharmaceutical company directories and device market reports on the hub so brand, access, and supply teams share one channel narrative.',
        ],
      },
      {
        title: 'Privacy, incentives, and panel quality for consumer healthcare audiences',
        paragraphs: [
          'Healthcare consumer research requires clear consent, minimal retention of identifiable data, and incentive structures that do not distort medical decision reporting. BioNixus documents screening, speeder removal, and back-translation for multilingual markets.',
          'Where patient diaries or adherence tracking are used, protocols follow local ethics expectations and separate research moderation from promotional contact paths.',
          'Quality metrics are reported to sponsors: completion rates, quota attainment by segment, and stability of theme libraries in qual modules—so governance teams can trust inference before campaigns scale.',
        ],
      },
    ],
    faqs: [
      {
        question: 'Does BioNixus run consumer research for pharmaceutical brands?',
        answer:
          'Yes. Programmes cover OTC, consumer health, vaccine, and Rx-adjacent shopper and patient insight with healthcare-compliant moderation and segmentations tied to launch and access decisions.',
      },
      {
        question: 'What is B2B healthcare market research?',
        answer:
          'Research with pharmacists, wholesalers, hospital procurement staff, and key accounts to understand listing, substitution, tender, and trade terms that shape uptake alongside clinician preference.',
      },
      {
        question: 'Which regions are covered for consumer and B2B work?',
        answer:
          'Primary depth in MENA and Africa, with coordinated modules in Europe and selected Americas markets through BioNixus regional field partners.',
      },
      {
        question: 'How do consumer studies integrate with physician research?',
        answer:
          'Shared hypotheses and harmonised segment labels allow medical, access, and brand teams to align narratives; field waves can be sequenced to avoid contradictory messaging tests in the same planning window.',
      },
      {
        question: 'What deliverables should teams expect?',
        answer:
          'Segment dossiers, channel and message test results, objection libraries for trade audiences, and executive summaries linking findings to KPI owners—not raw tables without strategic interpretation.',
      },
    ],
  },
};

export function getVideoWatchGuide(slug: string): VideoWatchGuide | undefined {
  return VIDEO_WATCH_GUIDES[slug];
}
